# *Neoadjuvant Therapy (NAT)*

**Cancer** Breast

**Question** Which breast cancer patients will respond to neoadjuvant chemotherapy administered before surgery to shrink the tumour?

**Benefits** Provides rapid clinical decision making and guides post-surgery therapy based on tumour's response

**Funding** UKRI IAA Nov 2024 – Oct 2025

| | *Total* | *Yes* | *No* | *Validation* |
|---|---|---|---|---|
| **# Patients** | 33 | 14 | 19 | – |
| **# Spectra** (K) | 8500 | 2500 | 6000 | – |

**Result** (AUC) 72% (including patients who relapsed)
82% (excluding patients who relapsed)

**Publication(s)** –

**Wavenumbers**

| *DNA/RNA* | | | *Amide III* | | *Amide II* | *Amide I* | MLA v2.1 |
|---|---|---|---|---|---|---|---|
| | | | | | | | |